@Grainger: (Post top of page) From the same site you linked to on the same day a few hours later (all very confusing lol):
"Gilead's Remdesivir Might Be As Good As It Gets"
"Drugs (mostly not yet developed) addressing immune system over-reaction for late stage acute disease might have a role. Mesoblast Remestemcel-L is possible but probably too expensive."
"Another company investigating COVID-ARDS is Mesoblast (MESO) which has a mesenchymal stem cell product, remestemcel-L, which is being trialed for end stage COVID-19, where the fatality rate is extremely high. Remestemcel-L is a very high cost live cell product which, even if it works, would have a limited market because of the very high cost."
https://seekingalpha.com/article/4352097-covidminus-19-gileads-remdesivir-might-be-good-gets?app=1&utm_medium=email&utm_source=seeking_alpha&mail_subject=pre-market-summary-on-your-portfolio-portfolio-1&utm_campaign=nl-portfolio&utm_content=link-4
Seems things are hotting up.
Cell Therapy News/Articles, page-3226
-
- There are more pages in this discussion • 14,598 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.31 |
Change
0.150(13.0%) |
Mkt cap ! $1.490B | |||
| Open | High | Low | Value | Volume |
| $1.15 | $1.33 | $1.15 | $25.26M | 19.99M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 7 | 161000 | $1.30 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.31 | 50400 | 2 |
View Market Depth
| Last trade - 16.10pm 23/07/2024 (20 minute delay) ? |
| MSB (ASX) Chart |